Contrave vs Mounjaro: Comparing Older and Newer Weight Loss Options

Last reviewed: July 12, 2026

Last updated: July 12, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Weight loss medications have evolved significantly over the past decade. Contrave, approved in 2014, combines naltrexone and bupropion through a different mechanism than newer agents like Mounjaro, which activates both GLP-1 and GIP receptors to produce stronger metabolic effects. Choosing between these options requires understanding both their clinical evidence and how they align with individual genetic predispositions.

How Contrave Works: Older Combination Therapy Approach

Contrave pairs two established drugs—naltrexone and bupropion—that work on different brain pathways. Naltrexone blocks opioid receptors in the hypothalamus, while bupropion, an antidepressant, increases dopamine and norepinephrine signaling. Together, they aim to reduce hunger signals and increase energy expenditure through central nervous system activation rather than hormonal changes.

Clinical trials show Contrave produces average weight loss of 5-9% of baseline body weight over one year. The medication requires four tablets daily (taken as two doses), and efficacy depends on consistent dosing and dietary modification. Response varies widely between individuals, partly due to differences in how patients metabolize bupropion and respond to dopaminergic stimulation.

Mounjaro and GLP-1/GIP Receptor Agonists: Newer Hormonal Approach

Mounjaro (tirzepatide) represents a newer class that mimics two natural gut hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By activating both receptors simultaneously, tirzepatide produces stronger appetite suppression, slower gastric emptying, and improved insulin sensitivity than single-hormone GLP-1 agents alone. Clinical data from SURMOUNT trials demonstrate average weight loss of 15-22% of baseline body weight—approximately double Contrave's effect.

Unlike Contrave's daily pill burden, tirzepatide is administered as a once-weekly subcutaneous injection. The medication's hormonal mechanism produces more consistent physiological changes across diverse patient populations. Patients experience reduced food cravings and increased satiety at lower caloric intake, supporting greater long-term adherence.

Key Differences in Efficacy, Side Effects, and Tolerability

Efficacy comparisons show tirzepatide achieves superior weight loss outcomes in head-to-head analysis. However, tirzepatide carries a higher incidence of gastrointestinal side effects—nausea, vomiting, and diarrhea—particularly during dose escalation, whereas Contrave's adverse events center on stimulation-related effects like insomnia and tremor. Individual tolerance depends partly on genetic variants affecting GLP-1 receptor sensitivity and gastrointestinal motility.

Contrave may be preferred by patients with contraindications to GLP-1/GIP therapy, such as personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Conversely, patients with diabetes or metabolic dysfunction often see greater benefit from tirzepatide's dual-receptor activation, which improves glycemic control alongside weight reduction.

Cost and Access: Prescription Options at PlexusDx

Mounjaro's brand cost frequently exceeds $1,200 monthly without insurance, while compounded tirzepatide through licensed 503A pharmacies reduces this barrier significantly. PlexusDx offers Compounded Tirzepatide Injection at $289/mo month-to-month, or from $249/mo on the 6-month plan—a fraction of brand pricing—with flat monthly pricing that remains constant regardless of dose level. No insurance is required, and medications are HSA/FSA eligible for eligible patients.

The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Genetic Predictors of Response: Why One Option May Work Better for You

Genetic variation in hormone receptors and appetite-regulating pathways significantly influences medication response. The GLP1R rs6923761 variant, for example, affects how efficiently cells respond to GLP-1 signaling, while the GIPR rs1800437 variant modulates GIP receptor function. Patients carrying specific allele combinations may experience substantially stronger appetite suppression with tirzepatide compared to those with different genetic profiles.

PlexusDx's Precision Peptide Genetic Test maps 14 distinct pathways and analyzes 150+ genetic insights across 49 peptides involved in weight regulation and metabolism. This analysis helps identify whether a patient's genetic profile suggests optimal response to tirzepatide's dual-hormone mechanism or whether alternative approaches might prove more effective. Understanding individual genetic predispositions supports precision medicine—matching medication choice to biology rather than trial-and-error prescribing.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Contrave still a good choice if I want to avoid injections?

Contrave is an oral option that avoids needles, but its lower efficacy (5-9% weight loss) means treatment typically lasts longer than newer agents. PlexusDx offers Oral Tirzepatide at $349/mo month-to-month, or from $279/mo on the 6-month plan—a tablet-based alternative to injections that delivers superior weight loss with GLP-1/GIP mechanism intact.

How much weight loss should I expect with each medication?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I get compounded tirzepatide if I don't have insurance?

Yes. PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization. Compounded Tirzepatide Injection is $289/mo month-to-month (or $249/mo on the 6-month plan) through licensed 503A pharmacies, with your dose able to increase while your price remains flat.

Which medication is safer for long-term use?

Both carry established safety profiles. Contrave's risks relate to stimulant effects and antidepressant warnings, while tirzepatide's primary concern is GI side effects during dose adjustment. Neither is recommended for personal or family history of medullary thyroid cancer. Your provider should review individual contraindications.

How does genetic testing help me choose between these medications?

No — the Precision Peptide Genetic Test does not predict your response to Mounjaro or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week
• Weight Loss Injections Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.